MODIFICATION
A -- ADAPTIVE OPTICS-BASED OPTICAL COHERENCE TOMOGRAPHY A New Standard of Imaging for the Early Diagnosis of Blinding Diseases
- Notice Date
- 9/14/2010
- Notice Type
- Modification/Amendment
- NAICS
- 238990
— All Other Specialty Trade Contractors
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue, L-795, Livermore, California, 94550
- ZIP Code
- 94550
- Solicitation Number
- FBO227-10
- Archive Date
- 10/12/2010
- Point of Contact
- Connie L Pitcock, Phone: 925-422-1072
- E-Mail Address
-
pitcock1@llnl.gov
(pitcock1@llnl.gov)
- Small Business Set-Aside
- N/A
- Description
- Opportunity : Non-invasive, compact, ultra-high resolution, three-dimensional retina imaging at the cellular level in real-time (~$2B-3B market) Background : Millions of people suffer from eye diseases that degrade the retina, causing blindness. Opthalmologists observe the retina to diagnose a wide variety of blinding diseases. Conventional equipment, however, does not provide cellular-level resolution to enable the doctor to make a more accurate diagnosis. Description : This technology uses microelectromechanical systems (MEMS), adaptive optics (AO), and optical coherence tomography (OCT) to produce 3-D retina images at the cellular level. AO compensates for optical aberrations by continuously sampling images, and rapidly compensating for these aberrations via a wavefront corrector. MEMS reduce the size and cost of the system without sacrificing speed or accuracy. See attached article and videos for more technical information. Advantages : •· Adaptive Optics-based OCT à Ultra-high resolution and 3-D sectioning à In vivo characterization at the cellular level à Early diagnosis of retinal diseases à Lower health care costs for both the patient and the health care provider •· MEMS-based system à Compact design à Lower manufacturing costs •· Reduced illumination à Maximum patient comfort during clinical session •· Digitized clinical record à Ability to monitor disease and effects of treatment Applications: •· Ophthalmology •· Clinical trials to monitor treatment effects of drugs •· Other fields (e.g., cardiology, dentistry, dermatology, oncology, etc.) that require imaging at the cellular level Development Status : Two functioning prototypes: one tested at UC Davis in 2005 and a second one tested at Indiana University in 2006. Both have been clinically tested on >100 patients. LLNL has been working on a compact version since 2007. This technology is a prestigious 2010 R&D 100 Award winner http://www.rdmag.com/Awards/RD-100-Awards/R-D-100-Awards/. IP Status : •· US Patent No. 7,791,734, 09/07/2010 •· US Patent Application Publication No. 2010/0149490
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DOE/LLNL/LL/FBO227-10/listing.html)
- Record
- SN02281497-W 20100916/100915000214-5b49438e4a599e27782dcc88d1689c04 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |